Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for chronic pelvic pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only within a multimodal management framework.
- ¿Qué evidencia existe?
- Tier C (investigational). One small case series (n=22) describes 30 to 40 percent reduction in pelvic pain VAS and improvement in quality-of-life measures following 4 to 6 leech sessions over 8 to 12 weeks, within a multimodal management plan. There are no controlled trials. Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6 to 15 percent of reproductive-age women. Standard care is multimodal: pelvic-floor physical therapy, cognitive behavioral therapy, trigger-point management, and pharmacotherapy (gabapentinoids, tricyclics, hormonal modulation). Single-modality use of any therapy is not recommended.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the lower abdomen, sacrum, or inner thigh for 5 to 10 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Triggering of additional pelvic-floor spasm if bite is near a trigger area
- Failure to address an underlying structural pathology if workup is incomplete
- Delay of evidence-based pelvic-floor physical therapy, CBT, or pharmacotherapy
- Substitution for multimodal therapy with single-modality leech sessions
- Quién no debería considerar esto
- Patients with untreated structural pathology (endometriosis, fibroids, ovarian cyst, adhesions) — workup first
- Patients with active pelvic infection (PID, abscess)
- Pregnant or lactating patients
- Patients with bleeding disorders or on anticoagulants
- Patients with severe anemia
- Patients who have not engaged with pelvic-floor physical therapy and behavioral therapy
- Qué preguntar a su clínico
- Has my workup excluded structural causes (endometriosis, fibroids, adhesions, ovarian pathology)?
- Am I receiving pelvic-floor physical therapy from a certified pelvic-floor PT?
- Have I been considered for cognitive behavioral therapy and pain psychology?
- Have neuropathic agents (gabapentin, duloxetine, tricyclics) been considered?
- Where exactly will the leech be placed, and what is the multimodal integration plan?
- What is the realistic expected benefit, given evidence is one small case series?
- Cuándo buscar atención urgente
- Sudden severe pelvic or abdominal pain (rule out acute pathology)
- Heavy or unusual vaginal bleeding
- Fever above 38.0 C / 100.4 F, chills, or pelvic tenderness
- Signs of infection (urinary, vaginal, gastrointestinal)
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, pus, or red streaks at any bite site
Qué NO significa esto
- It does not substitute for pelvic-floor physical therapy, cognitive behavioral therapy, or pharmacotherapy, which together have the strongest evidence.
- It does not work for structural pelvic pathology like endometriosis or fibroids, which need specific evidence-based treatment.
- It is not recommended as single-modality therapy — integration with the multimodal plan is essential.
- Only one small case series exists; benefit beyond multimodal therapy alone is uncertain.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- gynecologic
- ICD-10
- R10.2, N94.89
- Safety tier
- medium
Evidence Summary
Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6-15% of reproductive-age women. No controlled clinical trial or published case series of leech therapy for this condition exists; any use is investigational and mechanistic only. A proposed mechanism involves modulation of central sensitization and local pelvic-floor decongestion, but this is unproven. Any exploratory use should be integrated with evidence-based care — pelvic-floor physical therapy, cognitive behavioral therapy, and trigger-point management — rather than used as a single modality.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Mohammadi M et al. (2018), n=22
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Untreated structural pathology (rule out before treatment)
- Active pelvic infection
Related Conditions
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.
Premenstrual Syndrome (Investigational)
Investigational adjunct for moderate PMS refractory to conventional therapy; small case series only; SSRI and combined hormonal contraception remain primary.